Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitazalimab - Alligator Bioscience

Next Previous
Drug Profile

Mitazalimab - Alligator Bioscience

Alternative Names: ADC 1013; JNJ 7107; JNJ-64457107; Vanalimab

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alligator Bioscience
  • Developer Alligator Bioscience; Erasmus MC; Janssen Biotech; Scandion Oncology; University of Pennsylvania
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • No development reported Cancer; Solid tumours

Most Recent Events

  • 13 Jun 2025 Alligator Bioscience plans a phase III trial for Adenocarcinoma
  • 20 May 2025 Alligator Bioscience announces intention to submit the regulatory application for mitazalimab in the US and the European Union
  • 20 May 2025 The European Medicines Agency (EMA) grants a waiver from conducting paediatric clinical trials for mitazalimab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top